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Abstract 
 
The small GTPase M-Ras is highly expressed in the central nervous system and plays 
essential roles in neuronal differentiation. However, its other cellular and physiological 
functions remain to be elucidated. Here, I clarify the novel functions of M-Ras in osteogenesis. 
M-Ras was prominently expressed in developing mouse bones particularly in osteoblasts and 
hypertrophic chondrocytes. Its expression was elevated in C3H/10T1/2 (10T1/2) 
mesenchymal cells and in MC3T3-E1 preosteoblasts during differentiation into osteoblasts. 
Treatment of C2C12 skeletal muscle myoblasts with bone morphogenetic protein-2 (BMP-2) 
to bring about transdifferentiation into osteoblasts also induced M-Ras mRNA and protein 
expression. Moreover, the BMP-2 treatment activated the M-Ras protein. Stable expression of 
the constitutively active M-Ras(G22V) in 10T1/2 cells facilitated osteoblast differentiation. 
M-Ras(G22V) also induced transdifferentiation of C2C12 cells into osteoblasts. In contrast, 
knockdown of endogenous M-Ras by RNAi interfered with osteoblast differentiation in 
10T1/2 and MC3T3-E1 cells. Osteoblast differentiation in M-Ras(G22V)-expressing C2C12 
cells was inhibited by treatment with inhibitors of p38 MAP kinase (MAPK) and c-Jun N-
terminal kinase (JNK) but not by inhibitors of MAPK and ERK kinase (MEK) or 
phosphatidylinositol 3-kinase. These results imply that M-Ras, induced and activated by 
BMP-2 signaling, participates in the osteoblastic determination, differentiation, and 
transdifferentiation under p38 MAPK and JNK regulation. 
 
Keywords: 
M-Ras; Osteoblast differentiation; Transdifferentiation; BMP-2; p38 MAPK; JNK 
 3
Introduction 
 
The Ras family of small GTPases performs crucial roles in a variety of cellular functions, 
including cell proliferation, differentiation, survival, and transformation, as well as 
physiological and pathological functions [1, 2]. The family comprises as many as 36 genes in 
human [3]. However, each member seems to possess specific functions. M-Ras was first 
cloned from mouse C2C12 myoblast and rat brain cDNA libraries, and is highly expressed in 
the central nervous system [4, 5]. Although M-Ras is phylogenetically relatively close to the 
classical Ras (H-Ras, K-Ras, and N-Ras) and R-Ras subfamilies, it evolved independently of 
classical Ras, R-Ras, and the other members of the family in metazoans [6]. This is consistent 
with the fact that M-Ras has specific amino acids in the extended effector domains in addition 
to throughout the whole sequence, as compared with the other members [4, 6]. 
 Classical Ras has multiple effector proteins including Raf (A-Raf, B-Raf, and C-Raf), 
phosphatidylinositol 3-kinase (PI3K), and Ral guanine nucleotide exchange factors (GEFs) 
[7]. Constitutively activated oncogenic Ras causes cellular transformation through the 
activation of these effector proteins. M-Ras shares several effector proteins with classical Ras 
and possesses specific effectors as well [8–12]. Neuronal differentiation in PC12 cells induced 
by nerve growth factor (NGF) requires sustained activation of the extracellular signal-
regulated kinase (ERK) pathway (Raf–MEK–ERK cascade) [13, 14]. M-Ras activated by 
NGF signaling is responsible for this sustained activation of the ERK pathway, resulting in 
the neuronal differentiation, whereas classical Ras activates the ERK pathway only transiently 
[5]. M-Ras also participates in dendrite formation in rat cortical neurons by activating the 
ERK pathway [15]. On the other hand, M-Ras activated by tumor necrosis factor- (TNF-) 
activates Rap1, leading to lymphocyte adhesion [16]. Other cellular or physiological functions 
of endogenous M-Ras and the signaling mechanisms involved remain to be elucidated, 
although exogenously expressed constitutively active M-Ras exerts several cellular functions, 
including the determination of particular cell lineage from hematopoietic stem cells [17–20]. 
 Bone morphogenetic proteins (BMPs) are involved in almost all processes associated 
with skeletogenesis [21, 22]. Various BMPs, such as BMP-2, -4, and -7, bring about the 
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determination of mesenchymal progenitor cells to osteoblastic lineage cells (preosteoblasts), 
differentiation of the preosteoblasts into osteoblasts, maturation of the differentiated 
osteoblasts, and apoptosis as a result of maturation. In addition, they regulate chondrocyte 
differentiation and chondrogenesis and play direct and indirect roles in osteoclastogenesis 
during skeletal development. BMP signaling is mediated by receptor-regulated R-Smad 
transcription factors, Smad1/5/8, and a common-mediator Co-Smad, Smad4. Although the 
Smad pathway is a well-characterized BMP signaling pathway, BMPs also induce other 
signaling pathways. Several lines of evidence indicate that BMPs activate multiple MAP 
kinase (MAPK) signaling pathways: ERK, p38 MAPK, and JNK pathways [23, 24]. BMP 
signaling induces Runx2 and osterix (Osx), transcription factors essential for osteogenesis. 
Runx2 directs multipotent mesenchymal cells to an osteoblastic lineage and differentiation of 
preosteoblasts to osteoblasts [25–27], whereas Osx is required for osteoblast differentiation 
and maturation represented by calcification [28]. The p38 MAPK and JNK pathways, 
activated through BMP signaling, are involved in osteoblast differentiation in cooperation 
with BMP–Smad signaling by activating Runx2 and Osx [29–31]. However, the signaling 
pathways linking the BMP receptor to the p38 MAPK or JNK pathway and those connecting 
Smads, p38 MAPK, or JNK to Runx2 or Osx remain obscure. In addition, the involvement of 
other unidentified signaling pathways that regulate osteoblast differentiation in cooperation 
with BMP signaling cannot be ruled out. 
 I found that M-Ras was prominently expressed in developing mouse bones and that its 
expression was induced during osteoblast differentiation. In addition, M-Ras was activated by 
BMP-2 stimulation. Thus, I examined the role of M-Ras in osteogenesis. Forced expression 
and knockdown of Mras revealed that M-Ras is involved in multiple steps of osteogenesis, 
i.e., osteoblastic determination, differentiation, and maturation. M-Ras also has the potential 
to cause transdifferentiation of myoblasts into osteoblasts. The M-Ras-induced osteogenesis 
was mediated by the activation of p38 MAPK and JNK. 
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Materials and methods 
 
Cell culture 
Mouse C3H/10T1/2 (10T1/2) mesenchymal progenitor cells [32] were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS [10T1/2 growth 
medium (GM)]. To induce osteoblast differentiation, 1.5  105 cells were cultured on a 35-
mm dish for 48 h in the growth medium and then cultured in growth medium containing 50 
M L-ascorbic acid and 10 mM -glycerophosphate (Ost DM) for 8 d by replacing the 
medium every 48 h. Recombinant human BMP-2 was provided by Astellas Pharma Inc. The 
same number of cells cultured in the growth medium was transferred to DMEM supplemented 
with 5% FBS and 0.1 g/ml BMP-2, and cultured for 3 d by replacing the medium every 24 h. 
To induce adipocyte differentiation, the same number of cells cultured in the growth medium 
was cultured for 48 h in growth medium containing 10 g/ml insulin, 0.5 mM 3-isobutyl-1-
methylxanthine, 0.1 mM indomethacin, and 1 M dexamethasone, and then for 24 h in 
growth medium containing 10 g/ml insulin. This cycle of replacing the medium was 
repeated thrice. Mouse MC3T3-E1 (MC3T3) preosteoblasts [33] were obtained from RIKEN 
BRC Cell Bank and were maintained in the alpha modification of minimum essential medium 
(-MEM) supplemented with 10% FBS (MC3T3 GM). Mouse C2C12 myoblasts [34, 35] 
were maintained in DMEM supplemented with 10% FBS (C2 GM). To induce osteoblast or 
adipocyte differentiation in MC3T3 or C2C12 cells, the cells were treated in a similar manner 
as were the 10T1/2 cells. 
 To determine signaling pathways involved in osteoblast differentiation, the following 
kinase inhibitors were added to Ost DM at final concentrations of 10 M: MEK inhibitor 
U0126 (Promega), PI3K inhibitor LY294002 (Promega), p38 MAPK inhibitor SB202190 
(Sigma), and JNK inhibitor SP600125 (Sigma). 
 
Detection of differentiated state 
To detect alkaline phosphatase (ALP) activity cytochemically, cells were fixed in 4% 
paraformaldehyde in PBS containing 2 mM MgCl2 for 15 min, left in ALP buffer (100 mM 
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NaCl, 50 mM MgCl2, and 100 mM Tris-HCl, pH 9.5) for 15 min, incubated in ALP buffer 
containing 0.1 mg/ml 5-bromo-4-chloro-3-indolyl phosphate p-toluidine salt and 1 mg/ml 
nitro blue tetrazolium chloride for 15–60 min, and then washed three times with water. 
Biochemical determination of ALP activity was conducted with LabAssay ALP (Wako Pure 
Chemical Industries). Protein concentration was determined by the method of Bradford. To 
detect calcification by von Kossa staining, formalin-fixed cells were incubated in 5% AgNO3, 
irradiated with ultraviolet light for 60 min, and treated with 5% Na2SO3 for 2 min. To detect 
adipocyte differentiation, formalin-fixed cells were stained with 3% Oil Red O in 60% 
isopropanol for 10 min. 
 
Immunoblotting 
Anti-rat M-Ras polyclonal antibody (pAb) [5] was absorbed with H-Ras protein and affinity-
purified with M-Ras through Formyl-Cellulofine (Seikagaku Corp.). Cultured cells were 
washed with PBS and lysed with a lysis buffer (1% Nonidet P-40, 5% glycerol, 50 mM Tris-
HCl, pH 7.5, 100 mM NaCl, 10 g/ml leupeptin, 0.1 mM phenylmethylsulfonyl fluoride, 1 
mM dithiothreitol, 1 g/ml pepstatin A, 10 mM Na3VO4, and 10 mM NaF). These samples 
were subjected to SDS-PAGE, and immunoblotting was carried out as described previously 
[36]. Primary antibodies used were anti-M-Ras pAb, anti--tubulin mAb E7 (Developmental 
Studies Hybridoma Bank, DSHB), anti-Myc mAb Myc1-9E10 (American Type Culture 
Collection, ATCC), anti-pan-Ras mAb RAS10 (Calbiochem), anti-GST mAb 5A7 (Wako), 
anti-ERK1/2 pAb, anti-phospho-ERK1/2 (Thr202/Tyr204) mAb E10, anti-Akt pAb, and anti-
phospho-Akt (Ser473) pAb (Cell Signaling Technology). The intensity of M-Ras bands was 
quantified with the ImageJ 1.42 program (NIH). 
 
Tissue sectioning and immunofluorescence microscopy 
Cryosections of E17.5 mouse tibia were prepared with a Leica Cryomicrotome CM1850 as 
described previously [5]. All mouse protocols were in accordance with by the guidelines of 
Chiba University. The sections were incubated with anti-M-Ras pAb or anti-Osx pAb 
(Abcam) and then with Alexa Fluor 488-goat anti-rabbit IgG (Invitrogen) and counterstained 
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with bisbenzimide H33258 (Hoechst 33258). The specimens were observed with a Zeiss 
Axioskop microscope equipped with phase-contrast and fluorescence optics. 
 
Transfection and establishment of stable transfectants 
The recombinant plasmids pCMV/Myc-Mras(wt), pCMV/Myc-Mras(G22V), and 
pCMV/Myc-Hras(G12V) harbor wild-type (wt) Mras, constitutively active Mras(G22V), and 
Hras(G12V) cDNAs, respectively, in pCMV/Myc vector [4]. 10T1/2 and C2C12 cells were 
transfected with these plasmids by using Lipofectamine LTX Reagent (Invitrogen) and 
FuGENE 6 Transfection Reagent (Roche), respectively. The stable transfectants were selected 
with 800 g/ml G418 as described previously [36]. 
 
RT-PCR 
RNA was prepared from cultured cells as described previously [37]. Quantitative reverse 
transcription (RT)-PCR was conducted as described previously [38]. 
 
Pull-down assay 
Activation of Myc–M-Ras, endogenous M-Ras, and classical Ras was analyzed by a pull-
down assay using the glutathione S-transferase (GST)-tagged Ras association (RA) domain of 
Nore1 and cell lysates of C2C12 cells or a Myc-tagged Mras(wt) stable transfectant as 
described previously [5]. The bound proteins were analyzed by immunoblotting with the anti-
Myc mAb and the anti-pan-Ras mAb. 
 
RNAi 
RNA interference (RNAi) of Mras was conducted by stably expressing short interfering 
RNAs (siRNAs) with pSilencer 2.1-U6 neo vector (Ambion). The target sequences of mouse 
Mras siRNA1 and 2 were 5’-AAGCATACAGAGATTGACAAT-3’ (nt 154–174 from the 
initiation codon) and 5’-ATGACCTAGTTAGAGTAATTA-3’ (nt 506–526), respectively. 
These siRNA-expressing pSilencer vectors were transfected to 10T1/2 and MC3T3 cells with 
Lipofectamine LTX Reagent. Stable transfectants were selected with G418 at the 
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concentration of 800 g/ml for 10T1/2 cells and 200 g/ml for MC3T3 cells. 
 
Flow cytometry 
Stable transfectants of C2C12 cells were cultured for 12 h under serum starvation conditions 
or in Ost DM. The cells were subjected to flow cytometry according to the protocol of Cell 
Signaling Technology. Briefly, harvested cells were fixed with 4% paraformaldehyde for 10 
min at 37C. The cells were permeabilized with ice-cold 90% methanol for 30 min and rinsed 
with the incubation buffer (0.5% BSA in PBS). They were incubated with anti-phospho-ATF-
2 (Thr71) pAb or anti-phospho-c-Jun (Ser73) pAb (Cell Signaling Technology) for 45 min 
and then with Alexa Fluor 488-conjugated goat anti-rabbit IgG for 30 min. The cells, 
resuspended in 0.5 ml of PBS, were analyzed with a BD FACSCalibur HG flow cytometer. 
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Results 
 
M-Ras is prominently expressed in bone 
We have shown that M-Ras is highly expressed in the mouse central nervous system, brain 
and spinal cord [4, 5]. Remarkably, M-Ras protein was present in mouse bone at a much 
higher level than in the brain (Fig. 1A). A good source of M-Ras was bone without bone 
marrow, whereas bone marrow contained a less amount of M-Ras. Thus, the localization of 
M-Ras protein in long bones of developing mice was assessed by immunofluorescence 
microscopy using an anti-M-Ras pAb. M-Ras was located to hypertrophic chondrocytes, 
which serve as scaffolds for endochondral ossification, as well as trabecular bone and bone 
collar, where osteoblasts are present, in embryonic day 17.5 (E17.5) mouse tibia (Fig. 1B). 
Autofluorescence of the bones and nonspecific fluorescence of the secondary antibody were 
negligible (Supplementary Fig. 1). The distribution of M-Ras in trabecular bone and bone 
collar was similar to that of Osx (Fig. 1C), consistent with a previous study showing Osx 
(Sp7) expression by in situ hybridization [28]. The distribution pattern of M-Ras is also close 
to that of Runx2 expression [39, 40]. These results suggest the involvement of M-Ras in 
osteoblast determination, differentiation, or maturation during osteogenesis in vivo. 
 
M-Ras is induced and activated during osteoblast differentiation 
Mouse 10T1/2 mesenchymal progenitor cells have the potential to differentiate into a variety 
of cell types including osteoblasts, chondrocytes, adipocytes, and skeletal myocytes [41, 42]. 
When 10T1/2 cells were cultured in the osteoblast differentiation medium (Ost DM), a subset 
of the cells showed activity of ALP, an osteoblast differentiation marker protein, by day 8 (Fig. 
2A). Under the same conditions, MC3T3 preosteoblasts differentiated very efficiently into 
osteoblasts, and most of the cells exhibited ALP activity at high levels (Fig. 2B). M-Ras 
protein was present in undifferentiated 10T1/2 and MC3T3 cells, and the amount increased 
severalfold during the osteoblast differentiation in both cells (Fig. 2A, B). By contrast, C2C12 
myoblasts showed no obvious ALP activity in Ost DM for at least 8 d (Fig. 2C). The level of 
M-Ras slightly decreased during culturing for 8 d in Ost DM. 
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 Treatment of 10T1/2 and MC3T3 cells with BMP-2 also gave rise to osteoblast 
differentiation within 3 d to extents similar to those cultured in Ost DM for 8 d (Fig. 2D, E). 
M-Ras protein was highly accumulated during differentiation in both of these cells. Although 
C2C12 myoblasts did not show ALP activity in Ost DM, they efficiently exhibited ALP 
activity within 3 d in BMP-2-containing medium (Fig. 2F). This result is consistent with 
previous findings [43]. Notably, M-Ras was prominently induced during BMP-2-generated 
osteoblast differentiation in C2C12 cells. 
 When 10T1/2 cells were cultured under adipocyte differentiation conditions (in Ad DM) 
for 8 d, they differentiated into adipocytes and accumulated lipid droplets, which were 
detected by Oil Red O staining (Fig. 2G). On the other hand, neither MC3T3 nor C2C12 cells 
accumulated lipid droplets for at least 8 d (Fig. 2H, I). The levels of M-Ras protein were 
almost constant in 10T1/2 and C2C12 cells cultured in Ad DM, regardless of whether the cells 
differentiated into adipocytes. In contrast, the M-Ras protein level increased in MC3T3 cells 
cultured in Ad DM. This is probably because MC3T3 cells easily differentiated into 
osteoblasts as detected by ALP activity staining even in Ad DM (Fig. 2H). Altogether, these 
results indicate that the elevation in M-Ras protein level is related to osteoblast differentiation 
but not to adipocyte differentiation. 
 Quantitative RT-PCR analysis showed that Mras mRNA was induced in C2C12 cells 
within 6 h after BMP-2 treatment (Fig. 3A). In contrast, the Hras mRNA level was not 
affected by this treatment. mRNAs of the osteoblast transcription factors, Runx2 and Osx, and 
the differentiation marker ALP were also induced between 6 and 24 h after BMP-2 treatment 
(Fig. 3A). Accordingly, BMP-2 stimulation induces Mras mRNA concurrently with or 
preceeding the expression of mRNAs of these osteoblast transcription factors and 
differentiation marker protein. 
 Furthermore, to address whether M-Ras is activated by BMP-2 treatment, I transfected 
C2C12 cells with Myc-tagged wt Mras cDNA and established a stable transfectant 
[C2/Mras(wt)]. I also established C2C12 cells stably transfected with Myc-tagged 
Hras(G12V) and Mras(G22V) cDNAs, encoding constitutively active mutants of H-
Ras(G12V) (Gly12 is substituted with Val) and M-Ras(G22V), respectively (C2/Hras and 
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C2/Mras). Activation of M-Ras was analyzed by a pull-down assay to detect the binding of 
M-Ras to the RA domain of Nore1 (Rassf5), which is an effector protein of M-Ras as well as 
of classical Ras [5, 44]. Both Myc–H-Ras(G12V) and Myc–M-Ras(G22V) in C2/Hras and 
C2/Mras cells stably bound to the Nore1 RA domain (Fig. 3B). When C2/Mras(wt) cells were 
stimulated with BMP-2, M-Ras was activated within 5 min, and the activation was sustained 
for more than 60 min (Fig. 3B). In contrast, endogenous classical Ras proteins were not 
activated by BMP-2 treatment (Fig. 3B). Treatment of C2C12 cells with BMP-2 also activated 
endogenous M-Ras within 1 d, and the activation was sustained for at least 3 d (Fig. 3C). 
Therefore, BMP-2 stimulation not only induces the expression of Mras but also activates M-
Ras protein in C2C12 cells, whereas it neither induces classical Ras expression nor activates 
classical Ras proteins. 
 
Forced expression of activated M-Ras induces osteoblast differentiation 
Since M-Ras was prominently expressed in osteoblasts in bones and its expression was highly 
induced during osteoblast differentiation, I examined whether activated M-Ras participates in 
osteoblast differentiation. To assess the differentiation-inducing ability of M-Ras, I transfected 
10T1/2 cells with Myc-tagged Mras(G22V) cDNA and established three stable transfectants 
(10T/Mras1–3). I also established two stable transfectants with Myc-tagged Hras(G12V) 
cDNA (10T/Hras1 and 2) to compare differentiation-inducing ability. These clones expressed 
Myc–M-Ras(G22V) and Myc–H-Ras(G12V) proteins, respectively, at high levels (Fig. 4A). 
Although wt 10T1/2 cells and 10T1/2 cells stably transfected with the pCMV/Myc vector 
(10T/vec) as a control showed ALP activity at moderate levels, all three 10T/Mras cell clones 
exhibited ALP activity at considerably high levels by day 8 in Ost DM (Fig. 4C). In contrast, 
10T/Hras cell clones did not show ALP activity (Fig. 4C). Even when 10T1/2 cells and these 
transfectants were cultured for 21 d in Ost DM, none were stained by von Kossa staining, 
indicating that calcification did not take place (data not shown). Consequently, overexpressed 
activated M-Ras facilitates osteoblast differentiation but cannot bring about osteoblast 
maturation in 10T1/2 cells. In contrast to the function of M-Ras, activated H-Ras inhibits 
osteoblast differentiation. When cultured in Ad DM for 8 d, 10T1/2 and 10T/vec cells 
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accumulated lipid droplets stained by Oil Red O, but none of the 10T/Mras or 10T/Hras cell 
clones accumulated lipid droplets (Fig. 4C). Thus, both the activated M-Ras and H-Ras 
interfere with adipocyte differentiation. 
 I next transfected C2C12 cells with Myc–Mras(G22V) and Myc–Hras(G12V) cDNAs 
and established three (C2/Mras1–3) and two (C2/Hras1 and 2) stable transfectants, 
respectively. These clones expressed Myc–M-Ras(G22V) and H-Ras(G12V) proteins, 
respectively, at high levels (Fig. 4B). All three C2/Mras cell clones showed ALP activity at 
remarkably high levels by day 8 in Ost DM, although neither C2/Hras cell clones nor wt 
C2C12 or control C2/vec cells exhibited ALP activity (Fig. 4D). The ALP activity was 
elevated 3–7-fold in the C2/Mras cell clones as detected by a biochemical assay (Fig. 4E). 
Quantitative RT-PCR analysis of Runx2, Osx, and Alp mRNAs showed that differentiated 
C2/Mras cells expressed all these mRNAs, but that C2/Hras cells did not express Osx, which 
is essential for osteoblast differentiation and maturation [28] (Fig. 4F). Although C2/Hras2 
cells expressed a low level of Alp mRNA, the ALP protein in the cells had marginal activity, 
as shown in Fig. 4D and E. Moreover, calcification detected by von Kossa staining took place 
in C2/Mras cell clones by day 21 but not in C2/Hras cell clones, C2C12, or C2/vec cells (Fig. 
4D). Therefore, the activated M-Ras can cause not only transdifferentiation in C2C12 cells 
into osteoblasts but also osteoblast maturation. 
 
Knockdown of endogenous M-Ras interferes with osteoblast differentiation 
Since the overexpressed activated M-Ras facilitated osteoblast differentiation in 10T1/2 cells 
and brought about transdifferentiation into osteoblasts in C2C12 cells, I next addressed 
whether endogenous M-Ras is required for osteoblast differentiation. To knock down 
endogenous M-Ras expression by RNAi, I transfected 10T1/2 cells with vectors expressing 
two siRNAs targeting Mras and established two stable transfectants for each siRNA 
[10T/Mras(i)1-1, 1-2, 2-1, and 2-2]. Although 10T1/2 cells stably expressing scrambled 
control siRNAs [10T/cont(i)] expressed M-Ras protein at a level equivalent to that in wt 
10T1/2 cells, all the 10T/Mras(i) cell clones had markedly reduced levels of M-Ras protein 
(Fig. 5A). By contrast, the levels of classical Ras proteins were unaffected in these 
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transfectants. None of the 10T/Mras(i) cell clones expressed ALP activity by day 8 in Ost DM, 
though 10T/cont(i) and 10T1/2 cells exhibited a moderate level of ALP activity (Fig. 5C). 
Accordingly, M-Ras expression is indispensable for osteoblast differentiation in 10T1/2 cells. 
 I also transfected MC3T3 cells with the two siRNA expression vectors and established 
two stable transfectants for each siRNA [MC/Mras(i)1-1, 1-2, 2-1, and 2-2]. M-Ras protein 
levels were strikingly reduced in all these MC/Mras(i) cell clones, compared with wt MC3T3 
cells and MC/cont(i) cells stably expressing scrambled control siRNAs (Fig. 5B). Classical 
Ras protein levels were unaffected in these transfectants. Although MC3T3 and MC/cont(i) 
cells showed high levels of ALP activity by day 4 in Ost DM, MC/Mras(i) cell clones 
exhibited lower levels of ALP activity (Fig. 5D). The ALP activity in MC/Mras(i) cell clones 
was about a half of that in MC3T3 and MC/cont(i) cells (Fig. 5E). When these cells were 
stimulated with BMP-2 for 48 h, the ALP activity in MC3T3 and MC/cont(i) cells was 
elevated about fivefold (Supplementary Fig. 2). Although the activity in MC/Mras(i) cell 
clones also increased about fivefold in response to BMP stimulation, it was still about a half 
of that in MC3T3 and MC/cont(i) cells (Supplementary Fig. 2). The results may suggest that 
M-Ras mediates BMP-2-induced osteoblast differentiation in MC3T3 cells but that other 
signaling pathways also participate in the differentiation. 
 MC3T3 and MC/cont(i) cells formed numerous calcified nodules detected by von Kossa 
staining within 12 d in Ost DM, whereas MC/Mras(i) cell clones scarcely formed such 
nodules (Figs. 5D, F). Quantitative RT-PCR analysis showed that Mras mRNA levels were 
also reduced in MC/Mras(i) cell clones cultured for 4 d in Ost DM (Fig. 5G). Among various 
osteoblast transcription factors and differentiation marker proteins, the levels of Runx2 mRNA 
were similar between MC/cont(i) cells and MC/Mras(i) cell clones, but those of Osx, Alp, and 
osteocalcin (Ocn) mRNAs were diminished in MC/Mras(i) cells (Fig. 5G). Runx2 is essential 
for the determination of multipotent mesenchymal cells to preosteoblasts, whereas Osx is 
required for the differentiation of preosteoblasts into osteoblasts [25–28, 45, 46]. In addition, 
osteocalcin is a marker of fully differentiated osteoblasts [46]. Thus, these results imply that 
M-Ras is essential for osteoblast differentiation by regulating the expression of 
differentiation-related genes in the MC3T3 preosteoblast cell line. 
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p38 MAPK and JNK are required for M-Ras-induced osteoblast differentiation 
Next, I examined the signaling mechanism of M-Ras-mediated osteoblast differentiation. M-
Ras causes sustained activation of the ERK pathway through activating B-Raf in PC12 cells 
stimulated with NGF [5, 11]. Endogenous and exogenously expressed M-Ras also activates 
JNK and regulates p38 MAPK [8, 20, 47]. In addition, M-Ras activates PI3K and its 
downstream kinase Akt, leading to the prevention of apoptosis in PC12 cells [8]. Moreover, 
p38 and JNK are activated during osteoblast differentiation in a differentiation medium or by 
BMP-2 treatment and are involved in osteoblast differentiation [48, 49]. Thus, I treated 
C2/Mras cells cultured in Ost DM with inhibitors of MEK (U0126), PI3K (LY294002), p38 
(SB202190), and JNK (SP600125) and analyzed the effects of these inhibitors on osteoblast 
differentiation. These inhibitors did not exhibit any cytotoxicity at the concentrations used (10 
M) because they did not greatly affect or decrease the cell numbers for 4 d (Supplementary 
Fig. 3A). However, they suppressed the activities of MEK, PI3K, p38, and JNK in C2/Mras 
cells as detected by immunoblotting of phospho-ERK1/2 and phospho-Akt (Supplementary 
Fig. 3B, C) and by flow cytometry of phospho-ATF2 and phospho-c-Jun (Supplementary Fig. 
3D, E). 
 The addition of U0126 or LY294002 did not affect ALP activity in the C2/Mras cell 
clones as detected by cytochemical staining and biochemical analysis (Fig. 6A, B). By 
contrast, the addition of SB202190 and SP600125 strongly blocked ALP activity in all three 
C2/Mras cell clones (Fig. 6A, B). Consequently, the p38 and JNK pathways, but not the ERK 
pathway or PI3K signaling, are likely to be required for osteoblast differentiation in C2/Mras 
cells. 
 BMP-2-activated p38 and JNK phosphorylate to activate transcription factors ATF-2 and 
c-Jun, respectively, and these activated transcription factors interact with Smads [29, 48, 50, 
51]. Thus, to determine whether p38 and JNK are activated by M-Ras in C2/Mras cells, I 
analyzed the activating phosphorylation levels of ATF-2 and c-Jun with phospho-antibodies to 
them by flow cytometry. All three C2/Mras cell clones showed somewhat higher fluorescence 
intensity than did control C2/vec or C2/Hras cells (Fig. 6C, D). These results might imply that 
M-Ras activates, in addition to the p38 and JNK pathways, other signaling pathways required 
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for osteoblast differentiation in C2/Mras cells. 
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Discussion 
 
Although M-Ras is known to be highly expressed in the mouse central nervous system [4–6] 
and essential for neuronal differentiation [5, 11, 15], I have shown here that M-Ras is 
prominently expressed in bones. It was localized to hypertrophic chondrocytes as well as to 
the trabecular bone and bone collar, where osteoblasts are present, in the long bones of fetal 
mice. The distribution of M-Ras in the fetal mouse long bone is similar to that of Runx2 [39, 
40], which directs multipotent mesenchymal cells to an osteoblastic lineage and 
differentiation from preosteoblasts to osteoblasts [25–27]. Runx2 is also involved in 
chondrocyte hypertrophy in collaboration with Runx3 [40, 52, 53], as inferred from its 
localization in hypertrophic chondrocytes. In contrast, Osx, which is transactivated by Runx2 
[54] and highly expressed in trabecular bone and bone collar but not in hypertrophic 
chondrocytes, is exclusively required for osteoblast differentiation and maturation [28]. 
Accordingly, the distribution of M-Ras suggests the participation of M-Ras in osteoblast 
differentiation or osteogenesis. In addition, it would be intriguing to determine whether M-
Ras is also involved in chondrocyte differentiation or maturation. 
 In the cultured cell lines, M-Ras was induced during lineage determination from 
mesenchymal progenitor cells to preosteoblasts and during differentiation into osteoblasts 
both in Ost DM and by stimulation with BMP-2. It was also induced during 
transdifferentiation from myoblasts to osteoblasts by BMP-2 treatment. BMP-2 brought about 
not only the induction of M-Ras mRNA and protein expression but also the sustained 
activation of M-Ras protein. These results imply that certain signaling pathways activated by 
both Ost DM and BMP-2 lead to the expression of M-Ras and that a BMP-2-induced 
signaling pathway further activates a GEF acting on M-Ras. M-Ras is activated by a variety 
of growth factors or cytokines including NGF, fibroblast growth factor 2 (FGF2), epidermal 
growth factor (EGF), hepatocyte growth factor (HGF), colony stimulating factor-1 (CSF-1), 
interleukin-3 (IL-3), and TNF-, depending on cell type [5, 11, 16, 55–57]. NGF induces not 
only a transient activation of classical Ras but also a sustained activation of M-Ras leading to 
a sustained activation of the ERK pathway, which is required for neuronal differentiation in 
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PC12 cells [5]. Similarly, EGF causes a transient activation of H-Ras and a sustained 
activation of M-Ras in astrocytes [57]. BMP-2 also caused a sustained activation of M-Ras, 
whereas classical Ras proteins were not activated. Consequently, distinct GEFs and GTPase 
activating proteins (GAPs) seem to act on M-Ras and classical Ras in these signaling 
pathways. On the other hand, induction of M-Ras expression at the mRNA level has been 
reported in other systems such as IL-9-stimulated helper T cell lines [55], IL-6-stimulated 
epithelial cells [58], and the hypothalamus under thermal conditioning [47]. Thus, BMP-2 is 
the first signaling molecule that causes both the activation and expression of M-Ras. Since 
BMPs stimulate not only canonical Smad signaling but also the ERK, JNK, and p38 MAPK 
signaling pathways [21, 22, 24], it is necessary to determine which pathways are responsible 
for M-Ras expression and activation, respectively, and whether M-Ras induces any of these 
MAPK signaling pathways. 
 10T1/2 mesenchymal cell clones stably expressing M-Ras(G22V) (10T/Mras) very 
efficiently differentiated into osteoblasts when they were cultured in Ost DM. In addition, the 
knockdown of endogenous M-Ras expression in 10T1/2 cells and in MC3T3 preosteoblasts 
interfered with osteoblast differentiation. Thus, M-Ras is indispensable for both osteoblastic 
lineage determination and osteoblast differentiation. Furthermore, C2C12 myoblast cell 
clones stably expressing M-Ras(G22V) (C2/Mras) differentiated into osteoblasts in Ost DM, 
implying that M-Ras can also give rise to transdifferentiation of myoblasts into preosteoblasts. 
BMP-2 also causes osteoblastic determination, differentiation, and transdifferentiation from 
myoblasts to osteoblasts [43], as does M-Ras. Accordingly, M-Ras expressed and activated by 
BMP-2 signaling is likely to play crucial roles in the BMP-2-induced osteogenic effects at 
least in these cultured cell systems. Although osteoblast differentiation, detected by ALP 
activity, was efficiently induced in both 10T/Mras and C2/Mras cells cultured in Ost DM, 
calcification was generated in C2/Mras cells but not in 10T/Mras cells. This might be due to 
the lack of induction of the factors necessary for calcification in 10T1/2 cells but not in 
C2C12 cells because calcification did not take place in 10T1/2 cells but occurred in C2C12 
cells by stimulation with BMP-2 (data not shown). This result also supports the above notion 
that M-Ras mediates BMP-2 signaling for osteogenesis in these cultured cell systems. 
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 Many lines of evidence indicate that BMP-2/4-induced osteoblast differentiation is 
mediated by the p38 MAPK and JNK pathways as well as Smad signaling [24, 29, 48, 59, 60]. 
Smad signaling and the p38 or JNK pathway act both independently and interdependently on 
differentiation [21, 61]. In addition, the p38 and JNK pathways are required for osteoblast 
differentiation under other differentiation conditions [49, 62]. By contrast, although the ERK 
pathway is also activated under these differentiation conditions, its role in osteoblast 
differentiation is controversial. Some researchers argue that the ERK pathway stimulates 
osteoblast differentiation [63–65], whereas others report that it is involved in cell proliferation 
and not necessary for osteoblast differentiation and even negatively regulates the 
differentiation [49, 59, 62, 66]. These discrepancies might be ascribable to experimental 
conditions used, including cell type, differentiation stage, and conditions to induce 
differentiation. M-Ras-induced osteoblast differentiation in C2/Mras cells was prevented by 
inhibiting p38 or JNK but not by inhibiting the ERK pathway or PI3K, indicating that the p38 
and JNK pathways but not the ERK pathway or PI3K signaling are required for M-Ras-
induced osteoblast differentiation. The activation or regulation of p38 and JNK in M-Ras-
mediated signaling has been shown in other cellular or physiological systems [8, 19, 47]. 
Although the activities of p38 and JNK were somewhat elevated as shown by the 
phosphorylation of their substrates ATF-2 and c-Jun in C2/Mras cells, these levels may not 
have been sufficient for osteoblast differentiation. Therefore, M-Ras seems to activate, in 
addition to the p38 and JNK pathways, other signaling pathways responsible for the osteoblast 
differentiation. 
 In conclusion, I have shown that endogenous M-Ras participates in the induction of 
osteoblastic determination and differentiation in cultured cell systems. When overexpressed, 
M-Ras causes transdifferentiation of myoblasts into osteoblasts. Endogenous M-Ras also 
plays essential roles in NGF-induced neuronal differentiation [5], dendrite formation in 
cortical neurons [15], and TNF--induced lymphocyte adhesion [16]. In addition, 
exogenously expressed M-Ras has the potential to induce epithelial-mesenchymal transition 
and tumorigenesis in a mammary epithelial cell line [17, 18] as well as determination of a 
particular cell lineage from hematopoietic stem cells [19, 20]. Future extensive and intensive 
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studies would uncover the broader spectrum of cellular and physiological functions of M-Ras. 
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Figure legends 
 
Fig. 1  Prominent expression of M-Ras in bone. (A) M-Ras protein levels in brain and bone 
detected by immunoblotting. The amount of protein was normalized to -tubulin. Higher 
amounts of M-Ras were present in whole bone (femur) and bone without bone marrow (w/o 
BM) than in brain or bone marrow in adult mice. (B) Immunofluorescent localization of M-
Ras in E17.5 mouse tibia. Cryosections were observed by phase-contrast microscopy and by 
immunofluorescent staining with anti-M-Ras pAb (green) and counterstaining of the nuclei 
with H33258 (blue). Boxed areas in the left and center panels are shown at a higher 
magnification in right panels. Scale bars, 100 m (left and center panels) and 25 m (right 
panels). (C) Comparison of immunofluorescent localization of M-Ras and Osx in E17.5 
mouse tibia. Serial cryosections were stained with anti-M-Ras and anti-Osx pAbs. Scale bar, 
100 m. 
 
Fig. 2  Induction of M-Ras protein during osteoblast differentiation but not during adipocyte 
differentiation. (A–C) M-Ras protein levels and ALP activity staining in 10T1/2 (A), MC3T3 
(B), and C2C12 cells (C) cultured in Ost DM for 8 d. (D–F) M-Ras protein levels and ALP 
activity staining in 10T1/2 (D), MC3T3 (E), and C2C12 cells (F) cultured in BMP-2-
containing medium for 3 d. (G–I) M-Ras protein levels and Oil Red O staining or ALP 
activity staining in 10T1/2 (G), MC3T3 (H), and C2C12 cells (I) cultured in Ad DM for 8 d. 
M-Ras protein levels were analyzed by immunoblotting, quantified with ImageJ, and shown 
graphically. -Tubulin is shown as a standard. 
 
Fig. 3  Induction of Mras mRNA and activation of M-Ras protein in C2C12 cells by BMP-2 
treatment. (A) Induction of mRNAs of Mras, osteoblast transcription factors, and a 
differentiation marker Alp in C2C12 cells by BMP-2 treatment. C2C12 cells were treated with 
BMP-2, and mRNA levels were analyzed by quantitative RT-PCR. Time (h) after the BMP-2 
treatment is indicated. Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) mRNA is shown 
as a standard. (B) Activation of M-Ras but not classical Ras in C2/Mras(wt) cells by BMP-2 
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treatment. C2/Mras(wt) cells were treated with BMP-2, and activated M-Ras and endogenous 
classical Ras were detected by a pull-down assay using the GST–Nore1 RA domain. Time 
(min) after the BMP-2 treatment is indicated. Myc–M-Ras in cell lysates and pulled-down 
Myc–M-Ras were detected by immunoblotting with anti-Myc mAb. Endogenous classical 
Ras was detected with the anti-pan-Ras mAb. C2/Hras(G12V) and C2/Mras(G22V) cells were 
used as positive controls for the activation of H-Ras and M-Ras, respectively. (C) Activation 
of M-Ras in C2C12 cells by BMP-2 treatment. C2C12 cells were treated with BMP-2 for the 
number of days indicated, and activated M-Ras was detected by the GST–Nore1 RA domain 
pull-down assay. M-Ras in cell lysates and pulled-down M-Ras were detected by 
immunoblotting with anti-M-Ras pAb. 
 
Fig. 4  Induction of osteoblast differentiation by forced expression of activated M-Ras. (A) 
Exogenously expressed M-Ras(G22V) and H-Ras(G12V) in 10T/Mras and 10T/Hras cell 
clones, respectively. The amounts of Myc–M-Ras(G22V) and Myc–H-Ras(G12V) in stable 
transfectant clones were analyzed by immunoblotting with anti-Myc mAb. -Tubulin is 
shown as a standard. (B) Exogenously expressed M-Ras(G22V) and H-Ras(G12V) in 
C2/Mras and C2/Hras cell clones, respectively. (C) Facilitation of osteoblast differentiation 
and inhibition of adipocyte differentiation in 10T/Mras cell clones. 10T1/2, 10T/vec, 
10T/Hras, and 10T/Mras cell clones were cultured for 8 d in Ost DM, and osteoblast 
differentiation was detected by ALP activity staining. These cell clones were also cultured for 
8 d in Ad DM, and adipocyte differentiation was detected by Oil Red O staining. Scale bar, 
100 m. (D) Transdifferentiation into osteoblasts in C2/Mras cell clones. C2C12, C2/vec, 
C2/Hras, and C2/Mras cell clones were cultured for 8 d in Ost DM, and osteoblast 
differentiation was detected by ALP activity staining. They were also cultured for 21 d in Ost 
DM, and calcification was detected by von Kossa staining. Scale bar, 100 m. (E) ALP 
activity in C2/Mras and C2/Hras cell clones. The cells were cultured for 8 d in Ost DM, and 
ALP activity was analyzed biochemically. The values are means ± s.d. (error bars) of three 
independent experiments. *, P < 0.03 by t-test compared with C2C12 cells. (F) Induction of 
mRNAs of Runx2, Osx, and Alp in C2/Mras cell clones. The cells were cultured for 8 d in Ost 
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DM, and the mRNA levels were analyzed by quantitative RT-PCR. 
 
Fig. 5  Suppression of osteoblast differentiation by knockdown of endogenous M-Ras 
expression. (A) Interference with M-Ras expression in 10T/Mras(i) cell clones. The amounts 
of endogenous M-Ras and classical Ras in the cells cultured for 2 d in 10T1/2 GM were 
analyzed by immunoblotting with anti-M-Ras pAb and anti-pan-Ras mAb, respectively. -
Tubulin is shown as a standard. (B) Interference with M-Ras expression in MC/Mras(i) cell 
clones. The amounts of endogenous M-Ras and classical Ras in cells cultured for 2 d in 
MC3T3 GM were analyzed by immunoblotting. (C) Prevention of osteoblast differentiation in 
10T/Mras(i) cell clones. The cells were cultured for 8 d in Ost DM, and osteoblast 
differentiation was detected by ALP activity staining. Scale bar, 100 m. (D) Prevention of 
osteoblast differentiation in MC/Mras(i) cell clones. The cells were cultured for 4 d in Ost 
DM, and osteoblast differentiation was detected by ALP activity staining. They were also 
cultured for 12 d in Ost DM, and calcification was detected by von Kossa staining. Scale bar, 
100 m. (E) ALP activity in MC3T3 and siRNA cell clones. The cells were cultured for 4 d in 
Ost DM, and ALP activity was analyzed biochemically. The values are means ± s.d. (error 
bars) of three independent experiments. *, P < 0.03 by t-test compared with MC3T3 cells. (F) 
Area of calcified nodules formed in MC3T3 and siRNA cell clones. The cells were cultured 
for 12 d in Ost DM, and the area of calcified nodules detected by von Kossa staining was 
measured. The values are means ± s.d. (error bars) of three independent experiments. *, P < 
0.04 by t-test compared with MC3T3 cells. (G) Abrogation of mRNA expression of osteoblast 
transcription factors and differentiation marker proteins in MC/Mras(i) cell clones. The cells 
were cultured for 4 d in Ost DM, and the mRNA levels were analyzed by quantitative RT-
PCR. 
 
Fig. 6  Participation of p38 MAPK and JNK in osteoblast differentiation in C2/Mras cell 
clones. (A) Prevention of osteoblast differentiation by inhibitors of p38 MAPK and JNK. 
C2/Mras cell clones were cultured for 4 d in Ost DM or Ost DM containing 10 M each of 
U0126 (MEK inhibitor), LY294002 (PI3K inhibitor), SB202190 (p38 inhibitor), or SP600125 
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(JNK inhibitor). Osteoblast differentiation was detected by ALP activity staining. Scale bar, 
100 m. (B) ALP activity in C2/Mras cell clones treated with each inhibitor. The cells were 
cultured as in (A), and ALP activity was analyzed biochemically. The values are means ± s.d. 
(error bars) of three independent experiments. *, P < 0.02 by t-test compared with cells 
cultured in Ost DM without any inhibitors. (C) Flow cytometric analyses of phospho-ATF-2 
and phospho-c-Jun. C2/vec, C2/Hras, and C2/Mras cell clones were cultured for 12 h under 
serum starvation conditions. Cells incubated with anti-phospho-ATF-2 or anti-phospho-c-Jun 
pAb were analyzed by flow cytometry. 
 
Supplementary Fig. 1  Negligible levels of autofluorescence of bone and nonspecific 
fluorescence of secondary antibody. Serial cryosections of E17.5 mouse tibia were treated 
with Alexa Fluor 488-goat anti-rabbit IgG secondary antibody (left) and with anti-M-Ras pAb 
and then the secondary antibody (right). Scale bar, 100 m. 
 
Supplementary Fig. 2  ALP activity in MC3T3 and the siRNA cell clones treated with 
BMP-2. The cells were cultured for 48 h in MC3T3 GM containing BMP-2, and ALP activity 
was analyzed biochemically. The values are means ± s.d. (error bars) of three independent 
experiments. *,** P < 0.03 by t-test compared with MC3T3 cells with (**) or without (*) 
BMP-2 treatment. 
 
Supplementary Fig. 3  Effects of kinase inhibitors on C2/Mras cell clones. (A) Relative cell 
number of C2/Mras and C2/Hras cells cultured in Ost DM containing inhibitors. (B, C) 
Suppression of activating phosphorylation of ERK1/2 and Akt by treatment with U0126 (B) 
and LY294002 (C), respectively, in C2/Mras cells. The amounts of ERK1/2 and Akt and the 
levels of phospho-ERK1/2 and phospho-Akt were analyzed by immunoblotting. (D, E) 
Suppression of activating phosphorylation of ATF2 and c-Jun by treatment with SB202190 
(D) and SP600125 (E), respectively, in C2/Mras cells. The levels of phospho-ATF2 and 
phospho-c-Jun were analyzed by flow cytometry. 
